Endocrine Abstracts

BackgroundPrevalence of hypogonadism has been reported as high as 50% in men with T2DM and/or obesity. ADA and AACE Guidelines recommend assessment of hypogonadism in men with T2DM and obesity.Material and methodsIn a registry of 865 men with hypogonadism, 361 men (41.7%) had T2DM. 183 received TU 1000 mg/12 weeks (T-group), 178 opted against treatment (CTRL). Changes over time between groups were compared an...

BackgroundWhile almost all studies consistently show reduction of waist circumference as a result of testosterone therapy (TTh), effects on body weight are inconsistent and may depend on treatment duration, route of administration, and adherence.Material and methodsAfter excluding men with primary hypogonadism, 476 men with functional, symptomatic hypogonadism were obese. 281 men received testosterone undecan...

BackgroundEffects of testosterone therapy (TTh) on lipid parameters are inconsistent and may depend on treatment duration, route of administration, and adherence. While in short-term studies, testosterone usually lowers HDL, long-term studies seem to increase HDL. Total cholesterol, LDL and triglycerides are either reduced by TTh, or effects are neutral.Material and methodsAfter excluding men with primary hyp...

Introduction: Adrenocortical carcinomas (ACCs) are rare; incidence is approximately 1–2 per million population per year. These arefrequently aggressive tumours that may or may not be functional. The primary potentially curative treatment for ACC is surgery with currently mixed opinion among experts regardingadjuvant Mitotane treatment.The Case: 60 years old female was seen in clinic for work up of incidental adrenal mass. ...

Introduction: Adrenocortical carcinomas (ACCs) are rare; incidence is approximately 1–2 per million population per year. These arefrequently aggressive tumours that may or may not be functional. The primary potentially curative treatment for ACC is surgery with currently mixed opinion among experts regardingadjuvant Mitotane treatment.The Case: 60 years old female was seen in clinic for work up of incidental adrenal mass. ...

We report a 38 years old male who was referred to the endocrine clinic with 3 months history lethargy, lack of libido and reduced shaving frequency. He was previously fit and well with no past medical history however he and his wife has been trying for pregnancy for 2 years. He didn’t smoke, has no history of opioids use and drink 10 units of alcohol a week. His investigation showed panhypopiturism with profound low serum testosterone of <0.5 nmol/l (8.33–30.19),...

Introduction: Thyroid hormones are critical for early brain development, somatic growth, and bone and pubertal maturation. Primary hypothyroidism is a well-known cause of poor linear growth in children. This case highlights role of thyroid hormone replacement to improve final height in the setting of profound hypothyroidism.Case: We report the case of 16 years old Caucasian girl initially evaluated for primary amenorrhea and delayed growth of 139 cm putt...

Introduction: Dual oxidase 2(DUOX2) is NADPH oxidase complex at the apical membrane of the thyroid follicular cells which produce H2O2 required for thyroid hormone synthesis. DUOX2 gene mutation is a well known cause of congenital hypothyroidism (CH), the phenotype depends on the type of mutation and environmental factors.Case: We present a case of 29 years old female delivered a male baby with large neonatal goitre and severe CH who was started immediat...

Introduction: Hypogonadism is associated with metabolic syndrome and all its individual components. This study analysed effects of normalization of serum testosterone in mainly elderly, hypogonadal men.Methods: Prospective registry study of 252 men (mean age 60.6±8.0 years), with testosterone levels between ≤3.5 ng/ml. They received parenteral testosterone undecanoate 1000 mg at day 1, week 6 and every 12 weeks thereafter for up to 66 months.<...

Introduction: Testosterone therapy for hypogonadal men has been used for decades. However, there are still concerns regarding the safety of this treatment, particularly in elderly men.Methods: Prospective registry study of 252 men (mean age 60.6±8.0 years), with testosterone levels between ≤3.5 ng/ml. They received parenteral testosterone undecanoate 1000 mg at day 1, week 6 and every 12 weeks thereafter for up to 66 months.<p class="abst...